• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Infinity Pharmaceuticals Inc.

    2/14/22 10:41:40 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INFI alert in real time by email
    SC 13G 1 polar-infi123121.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Infinity Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    45665G303

    (CUSIP Number)

     

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  45665G303
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital Holdings Plc
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    5,000,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    5,000,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    5,000,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.6%
    12
    TYPE OF REPORTING PERSON
     
    HC

     


     

    CUSIP No.  45665G303
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    5,000,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    5,000,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    5,000,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.6%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No. 45665G303
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Infinity Pharmaceuticals, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1100 Massachusetts Avenue, Floor 4

    Cambridge, MA 02138

    Item 2.(a) Name of Person Filing:

    Polar Capital Holdings Plc

    Polar Capital LLP

     

    Item 2.(b,) Address of Principal Business Office:

    16 Palace Street

    London, SW1E 5JD

     

    Item 2.(c) Citizenship:

    United Kingdom

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.001 par value per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    45665G303

     

    CUSIP No.  45665G303
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 45665G303
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1:

    Polar Capital Holdings Plc

    (a) Amount beneficially owned: 5,000,000

    (b) Percent of class: 5.6%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 5,000,000

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 5,000,000

     

    Polar Capital LLP

    (a) Amount beneficially owned: 5,000,000

    (b) Percent of class: 5.6%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 5,000,000

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 5,000,000

     

    * Based on 89,015,398 shares, which is the total number of shares outstanding as reported in the Issuer's Form 10-Q on November 2, 2021.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person 

    Information for each Subsidiary is incorporated on the respective cover pages..

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 45665G303
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Samir Ayub
       

    Name: Samir Ayub

    Title: Group Finance Director 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           

     

     
    CUSIP No. 45665G303
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2022

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Samir Ayub
       

    Name: Samir Ayub

    Title: Group Finance Director 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
    Get the next $INFI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INFI

    DatePrice TargetRatingAnalyst
    10/18/2021$9.00Buy
    HC Wainwright & Co.
    8/2/2021$6.00Neutral → Overweight
    JP Morgan
    7/28/2021$4.00 → $14.00Equal-Weight → Overweight
    Wells Fargo
    7/7/2021$7.00Buy
    B. Riley Securities
    More analyst ratings

    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Infinity Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      10/18/21 6:27:01 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals upgraded by JP Morgan with a new price target

      JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00

      8/2/21 5:42:58 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously

      7/28/21 5:37:19 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    SEC Filings

    See more
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/29/23 4:04:01 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/13/23 8:11:15 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/11/23 4:09:04 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/14/23 3:59:19 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/9/23 11:22:21 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/14/22 2:01:09 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Perkins Adelene Q converted options into 768,133 shares and sold $28,714 worth of shares (410,196 units at $0.07), increasing direct ownership by 44% to 1,175,291 units

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      9/12/23 6:20:24 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Peluso Stephane converted options into 50,000 shares, increasing direct ownership by 1,711% to 37,052 units to cover taxes

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      8/4/22 6:26:16 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Evnin Anthony B was granted 46,378 shares, increasing direct ownership by 27% to 215,403 units

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      6/16/22 9:29:24 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

      Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the init

      7/25/23 4:05:00 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

      Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI"). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process o

      7/24/23 8:30:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

      MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined company with: a diversified therapeutic pipeline; a team that brings clinical development and regulatory expertise; and the capabilities and resources to develop new oncology therapeutics for the benefi

      7/19/23 8:00:00 AM ET
      $INFI
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Financials

    Live finance-specific insights

    See more
    • MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

      Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno

      2/23/23 7:00:00 AM ET
      $INFI
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

      – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 with $47.2 million in cash and cash equivalents at end of Q3 2022– – Investor conference call to be held today at 8:30 AM ET – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provi

      11/14/22 7:07:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

      Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022. To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page

      11/7/22 8:25:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care